menu
    • menu
    [{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"GV101","moa":"ROCK2","graph1":"Neurology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Ovid Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Ovid Therapeutics"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"GV101","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Graviton Bioscience

    Menu

    Graviton Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Graviton Bioscience

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Graviton Bioscience

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GV101

    Therapeutic Area : Immunology

    Study Phase : Phase I

    Sponsor : Sanofi

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    Graviton Receives Sanofi Investment to Advance Next-Generation ROCK2 Inhibitors

    Details : Through financing, Sanofi gains a right of first negotiation to license compounds like GV101 for various indications, including immunological and metabolic syndrome.

    Product Name : GV101

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 02, 2024

    Lead Product(s) : GV101

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Sponsor : Sanofi

    Deal Size : Undisclosed

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Graviton Bioscience

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Graviton Bioscience

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GV101

    Therapeutic Area : Neurology

    Study Phase : Phase I

    Sponsor : Ovid Therapeutics

    Deal Size : $10.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhib...

    Details : The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.

    Product Name : GV101

    Product Type : Other Small Molecule

    Upfront Cash : $10.0 million

    January 05, 2023

    Lead Product(s) : GV101

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Sponsor : Ovid Therapeutics

    Deal Size : $10.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth